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Abstract
Growing evidence indicates the safety and well toleration of treatment by 
Disease-modifying in children suffering multiple sclerosis (MS). The treatment 
is not straight forward in a great number of patients, thus patients with pediatric 
MS must be managed by experienced specialized centers. Common treatments 
of multiple sclerosis for adults are first-line therapies. These therapies (first-
line) are safe for children. Failure in treatment that leads to therapy alteration 
is almost prevalent in pediatric MS. Toleration against current second-line 
therapies has been shown in multiple sclerosis children. Oral agents have not 
been assessed in children MS patients. Although clinical trials in children are 
insufficient, immunomodulating managed children, experience a side effect 
similar to the adult MS patients. However, further prospective clinical studies, 
with large sample size and long follow-up are needed to distinguish the benefits 
and probable side effects of pediatric MS therapies. 
Keywords: Disease-modifying therapies; Pediatric MS; Multiple sclerosis; 
Treatment
Introduction
Multiple sclerosis (MS) is the immune-mediated demyelinated disease of the 
human-beings that mostly entangle young adults. Nevertheless, children MS 
estimated to be 10% of all cases. Clinical and laboratory findings have shown 
differences in the disease characteristics and response to the treatment among 
children and adults (1, 2). In general, pediatric MS less than 10 yr old occurred 
rarely and constitutes approximately 20% of the reported pediatric cases in large 
series (3).
There are increasing evidences about epidemiology, pathophysiology, diagnosis, 
and management of MS in children. Previous studies mainly investigated the role 
of genetic and environmental factors. Subtypes of Human Leukocyte Antigen 
(HLA) as well as exposure to viruses are the major potential candidates (4). 
Pediatric MS is more benign than adult MS. However, because of early age 
of onset, patients with pediatric MS achieve a noticeable degree of disability 
earlier than adult MS patients. Treatment of children with MS is mainly based 
on adult’s treatment (5). Retrospective data have indicated the efficacy of these 
treatments. An early initiation of treatment with disease modifying drugs in adults 
with relapsing remitting MS (RRMS), cause persistence slower development of 
disease (6). Yet, no randomized controlled trials of disease modifying therapies in 
children have been carried out (2, 7). 
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Management of MS in children
Management of pediatric MS is a controversy topic 
that recently attracted the attention. In this article we 
will review current management of pediatric MS.
 
Diagnosis 
Because of the broader spectrum of other childhood 
disorders with similar symptoms and characteristics, 
diagnosis of MS in children is more difficult in 
comparison with adult population (8). In addition, 
atypical clinical, biological, and MRI presentations 
cause more difficulties in distinguishing children MS 
patients (9). MS is historically defined as neurologic 
symptoms disseminated in space (DIS) and time 
(DIT). The diagnostic criteria for MS in adults have 
been changed during past years (10-12). The current 
McDonald diagnostic criteria may be accepted to 
children, if the beginning presentation is not identified 
by encephalopathy. Recently, formulated diagnostic 
criteria for pediatric MS may help to develop diagnostic 
precision for the clinicians. The International Pediatric 
MS Study Group (IPMSSG) published operational 
definitions for acquired demyelinating diseases of the 
CNS in children, in 2007 (13). According to definitions 
of the IPMSSG diagnosis of pediatric MS may be after 
two separated clinical episodes of demyelination in 
central nervous system (CNS) by at least 30 days (14). 
Table 1 shows the last diagnostic criteria mentioned 
for multiple sclerosis in children (The 2010 McDonald 
Criteria for Diagnosis of MS).
Treatment
First line disease modifying therapy
Disease modifying therapy (DMT)
First-line disease modifying therapies (interferon beta 
and glatiramer acetate) were initially approved for use 
in adults 15–20 yr ago and have since been safely used 
in children. 
Pediatric MS has been related with noticeable cognitive 
impairment (15) as well as lesions on MRI (8). In most 
cases, DMT can decrease the relapse rate and progression 
of the MS (16). Decreased probability of presentation 
with a later clinical relapse was the result of early 
treatment with DMT in pediatric MS (17). However, 
usage of DMT in MS patients whose symptoms of 
their first attack (clinically isolated syndrome) resolved 
completely with a low lesion load (<6 T2-bright lesions, 
<2 gadolinium enhancing lesions) is not recommended 
(18). DMT therapy is recommended if a second attack 
occurred within every 6 months follow up during two 
yr or in condition of active disease signs. four first-
line (glatiramer acetate (GA), intramuscular (IM) and 
subcutaneous (SC) interferon β-1a, and SC interferon 
β-1b), and two second-line therapies (mitoxantrone and 
natalizumab) are disease modifying therapies accepted 
for the management of relapsing–remitting MS 
(RRMS) for adult patients. Priority of these treatments 
has not been evaluated by randomized controlled trials. 
Additionally from country to country drug choice is 
different (6) (Table 2).
Interferon beta (lNFB)
Previous studies suggested that INFB is able to effect on 
MS through inhibition of proinflammatory cytokines, 
induction of anti-inflammatory mediators, reduction 
of cellular migration and inhibition of autoreactive T 
cells (19). Safety and toleration of subcutaneous and 
intramuscular INFB-1a and INFB-1b in pediatrics MS 
patients has been shown in retrospective and open label 
studies (20, 21). No data are available about the effect 
of INFB on MRI lesions and its usefulness on slowing 
down the process of disease in children. Side effects 
of INFB have been reported as: 1. Flu-like symptoms 
which reported in a great number of MS children (35%-
65%). 2. Leucopenia (8%–27%), 3. thrombopenia 
(16%), 4. anemia (12%) and 5. transient elevation in 
transaminases (10%–62%) (21, 22). Liver function tests 
(LFTs) in younger children taking interferon obviously 
showed abnormality (20). IPMSSG has recommended 
that the adjusted dosage of INFB should be used in 
pediatric MS patients, especially in those under 10 
years old. The starting dose should be 25 to 50% of 
the dosage administrated to adult with a gradually 
increasing every 2-4 weeks to reach optimum tolerable 
dose. In children under 10 years old, the treatment is 
initiated with 10% of the dosage which started in adult 
and gradually reaches to the maximum tolerable dose 
(Table 2). 
Glatiramer acetate (GA)
Glatiramer acetate is a heterogenous mixture of 
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synthetic polypeptides consisting of four amino acids 
(L-alanine, L-glutamic acid, L-lysine, L-tyrosine) 
found in myelin basic protein. Role of GA is to 
act as human myelin basic protein, activate myelin 
specific response of suppressor T lymphocytes and 
inhibit specific T lymphocytes. The therapy including 
daily subcutaneous administration of 20 mg GA and 
according to IPMSSGthere is no need to increase the 
dosage (23). The safety and well toleration of drug 
in pediatric MS patients is reported (14, 24). Three 
retrospective studies have been published assessing the 
efficacy of GA in pediatrics (16, 24, 25) (Table 2).
Side effects
IFN
Transient flu-like symptoms experienced by lots of 
patients during the first trimester of INFB therapy. 
Headache, transient elevation of the liver enzymes, 
leucopenia, anemia, thrombocytopenia, and thyroid 
dysfunction require monitoring during the process of 
treatment with IFN. These side effects are diminished 
usually by reduction of drug dosage. Exacerbation of 
depression symptoms by IFN should be mentioned in 
depressed patients and thus it is better to avoid IFN 
usage in these patients. Before administration of INFB, 
patients who suffered flu-like symptoms can be treated 
with ibuprofen 10 mg/kg (6, 22, 25, 26) (Table 2).
GA
Most common side effects is pain and indurations at the 
site of injection and transient systemic reactions (23). 
Transient skin retraction at the injection site as well as 
chest pain and flushing are complications happening 
immediately after the injection (21, 24)(Table 2).
Treatment in condition of exacerbation
Methyl Prednisolone pulse
Methyl prednisolon is an important drug in treatment 
of MS, especially in the acute phase of relapse. 
Decreasing the inflammatory process done through 
different pathways: dampening the inflammatory 
cytokine cascade, inhibiting the activation of T cells, 
decreasing the extravasations of immune cells into the 
central nervous system, facilitating the apoptosis of 
activated immune cells, and indirectly decreasing the 
cytotoxic effects of nitric oxide and tumor necrosis 
factor alpha (27)(Table 2).
Exacerbations in children have not been carried out 
yet, as far as we know. Thus, treatment for acute 
MS in the pediatric is extremely based on adult 
treatment. A study of US physicians recommend that 
many follow the management with the regimen of IV 
methylprednisolone 20–30 mg/kg/d (up to 1 gm) for 
3–5 days for acute MS exacerbations. Notably, not 
all children who experience acute, receive treatment. 
Supportive care may be recommended by some 
physicians if clinical manifestations are mild and do 
not lead to disability (28) (Table 2).
Intra Venous Immuno Globulin (IVIG)
Some case reports which try to manage with 
IVIG therapy in difficult managing cases of acute 
demyelinating in children patients with MS, suggest the 
probable improvement followed by mentioned therapy. 
However, patients were just those children with both 
optic neuritis and ADEM (29, 30) (Table 2).
Plasmapheresie
Plasma exchange (PE) is an efficient therapy for severe 
relapses of acute inflammatory CNS demyelinating 
diseases in adults. Therapeutic plasma exchange (TPE) 
has been useful in the treatment of several pediatric 
diseases. However, the safety and efficacy of this 
management in pediatric patients need to be more 
developed (31)(Table 2).
Therapy evaluation
The patients follow up should be done within 1, 3 and 
6 month after therapy and then every 6 month. Efficacy 
of treatment was evaluated by following the patients 
in mentioned time and performing the neurological 
examination. In addition, before starting the uptake of 
DMT, MRI scan must be performed. MRI scan should 
be repeated yearly in patients with stable condition 
(23).
If serious side effects are appearing or when side effects 
are not tolerated by patients and leading to reduced 
compliance, alteration in treatment is necessary. 
Furthermore, when the therapy is not as effective as 
expectation, drug choice should be changed. Yet, no 
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cells into the CNS (38). Natalizumab has been accepted 
for the management of relapsing forms of MS (RRMS) 
(39). Adult MS patients who require an escalation 
therapy are treated with natalizumab with a dosage 
of 3-5 mg/kg as an infusion every 4 wk. In only one 
pediatric study performed in Italy, natalizumab (300 
mg, every 28 days) was used in 19 children with severe 
active MS. After 15-month follow up relapses and 
MRI lesions suppressed in all patients and no serious 
side effects were reported (40). In Portugal, 383 cases 
were enrolled in natalizumab therapy and treatment 
with natalizumab was more effective in patients with 
less disability and without prior disease modifying 
therapy (41). However, natalizumab is not approved 
for patients less than 18 yr old and in some cases 
leads to progressive multifocal leukoencephalopathy 
(PML). Thus, natalizumab therapy must be restricted 
to specialized centers (6, 35, 37, 40, 42)(Table 2). 
Cyclophosphamide
Cyclophophamide has not been approved for 
the treatment of MS. But, prescription of pulse 
cyclophosphamide decrease disease activity in adult MS 
patients (43, 44). In a retrospective study, 17 children 
aged 9 to 18 yr were treated with cyclophosphamide 
at either pulse or induction therapy most of the cases 
indicated improvement of relapse frequency and EDSS 
1 yr after the initiation of cyclophosphamide therapy 
(37)(Table 2). 
Rituximab
Rituximab is not accepted for the treatment of MS, 
but positive effects has been indicated in adult 
RRMS that showed noticeable decrease of brain 
lesions and clinical relapses. A recent study assesses 
8 pediatric neuromyelitisoptica and 3 MS patients 
and reported that the use of rituximab in our pediatric 
neuromyelitisoptica and multiple sclerosis cohort was 
overall safe and effective (45-48)(Table 2).
Daclizumab
Intravenous daclizumab, has been used off-label in 
adult MS patients (49-52) and another subcutaneous 
form is being tested in clinical trials in adult MS. 
Recently, a study assessed the efficacy intravenous 
studies or suggestion for pediatric MS are available to 
guide the decision if therapy should be changed or not 
(6). 
In patients who are not able to tolerate the side effects 
of DMT, the treatment should be changed from INFB 
to GA or vice versa. No overlap or time delay between 
discontinuing the first drug and initiation of second 
one is acceptable. Dosage of INFB should be gradually 
increased as it introduced first as described above. 
Supporting the suboptimal response to DMT is based 
on the above mentioned suggestion and needs at least 
6 month time after the starting the treatment. However, 
individual decision for each patients must be taken as 
there is not follow a strict algorithm (32).
Failure in treatment: Second-line therapies
Therapy failure is a concern in the pediatric MS 
individuals. Failure in treatment is defined differently 
with a high controversy among physicians treating 
adult-onset MS.Six US Pediatric MS Centers of 
Excellence followed the 258 children with MS, 123 
(48%) children failed in their first line of treatment. 
Noncompliance and intolerable side effects were 
observed in a notable percentage of these patients. 
Thirty seven (16%) of patients switched their therapies 
as a result of noncompliance or side effects, 72 (28%) 
because of progression of disease, and 4% (12) due 
to discontinuation of treatment after the first agent 
(33). Yet, there is not any approved algorithm for 
the treatment of partial responsiveness, natalizamab, 
cyclophosphamide, mitoxantrone, and rituximab are 
the immunomodulatory and cytotoxic agents reported 
in pediatric MS patients resistant to therapy (34).
Escalation therapy 
Cyclophosphamide, mycophenolatemofetil, 
daclizumab, mitoxantrone, rituximab and natalizumab 
have been used in pediatric MS patients (35-37). 
However, their prescription in children has not been 
suggested yet.
Natalizumab
Natalizumab is a humanized monoclonal antibody 
that targets the a4 subunit of a4b1 and 4b7 integrins, 
molecules involved in the transmigration of immune 
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daclizumab in 7 pediatric MS patients treated largely in 
combination with beta interferons. This study indicated 
that treatment with daclizumab was in association with 
reductions in ARR, number of contrast enhancing 
lesions, and reduction or stabilization of EDSS in 
each patient. However, 4 patients had relapses and 
new contrast enhancing lesions during daclizumab 
treatment (53)(Table 2).
Side effect
Natalizumab: Hypersensitivity reactions and 
development of antibody to the drug. The most 
important side effect is a 1:1000 risk of progressive 
multifocal leukoencephalopathy (PML) observed in 
adult patients (54-56).
Cyclophosphamide: Side effects of cyclophosphamide 
include vomiting, transient alopecia, osteoporosis, and 
amenorrhea. Development of bladder carcinoma has 
been seen in one patients that was successfully treated 
(57, 58).
Rituximab: Probable side effect of rituximab is 
development of PML and other severe infection (50-
52)
Daclizumab: Elevated liver function tests, infections, 
psoriasis and oral ulcers are adverse effects related 
to intravenous daclizumab treatment (50-53, 59, 60)
(Table 2). 
Oral agents
Fingolimod, and cladribine for adult MS patients, 
influence the lymphocytes by various mechanisms. 
Yet, no study about usage of these two oral agents in 
pediatric MS patients has been published. However, 
negative effects founded in association with these agents 
in adult MS patients, consisting of cancer and lethal 
herpetic infections. Thus, adopting these therapies in 
pediatric population requires serious attention (61-63).
Fingolimod
Fingolimod is an orally administered small molecule 
that targets the sphingosine-1-phosphate receptor that 
is necessary for lymphocyte egress from lymph nodes. 
Fingolimod was approved for adult patients with MS. 
No information currently exists about fingolimod with 
regard to safety, tolerability and dosage in children (62, 
64-66)(Table 2).
In conclusion, Children appear to accrue locomotor 
disability more slowly, but they can have significant 
cognitive deficits, even early on in the course of the 
disease. There have been no randomized-controlled 
studies of disease-modifying therapies. However, first-
line therapies, beta interferon, and glatiramer acetate 
are extensively used off-label. Therapies in pediatric 
MS are being developed and may be implemented in 
the next few years.
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Table 1. Last Diagnostic Criteria Mentioned for Multiple Sclerosis in Children (The 2010 McDonald Criteria for 
Diagnosis of MS)
Clinical presentation Additional data needed for MS diagnosis
≥2 Attacksa; objective clinical evidence of 
>2 lesions or objective clinical evidence 
of 1 lesion with reasonable historical 
evidence of a prior attackb
Nonec
≥2 Atracksa; objective clinical evidence 
of one lesion
Dissemination in space, demonstrated by: ≥1 T2 lesion in at least 2 of 4 MS-typical 
regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord)d: or 
Await a further clinical attacka implicating a different CNS site
≥1 Attacka: objective clinical evidence of 
2 lesions
Dissemination in time, demonstrated by: Simultaneous presence of asymptomatic 
gadolinium-enhancing and non enhancing lesions at any time: or A new T2 and/or 
gadolinium-enhancing lesion (s) on follow-up MRI, irrespective of its timing with 
reference to a baseline scan; or Await a second clinical attacka
≥1 Attacka: objective clinical evidence of 
1 lesion (clinically isolated syndrome)
Dissemination in space and time, demonstrated by:
For DIS: 1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS (periventricular, 
Juxtacortical, infratentorial, or spinal cord)d; or Await a second clinical attacka 
implicating a different CNS site: and
For DIT: Simultaneous presence of asymptomatic gadolinium-enhancing and 
nonenhancing lesions at any time; or A new T2 and/or gadolinium-enhancing lesion(s) 
on follow-up MRI irrespective of its timing with reference to a baseline scan; or Await 
a second clinical attacka
Insidious neurological progression 
suggestive of MS (PPMS)
One year of disease progression (retrospectively or prospectively determined) plus 2 
of 3 of the following criteriad:
1. Evidence for DIS in the brain based on 1 T2 lesions in the MS characteristic 
(periventricular, juxtacortical, or infratentorial) region
2. Evidence for DIS in the spinal cord based on 2 T2 lesions in the cord
3. Positive CSF (isoelectric focusing evidence of oligoclonal bands and/ or elevated 
IgG index)
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If the criteria are fulfilled and there is no better 
explanation for the clinical presentation, the diagnosis is 
“MS”; if suspicious, but the criteria are not completely 
met, the diagnosis is “possible MS”; if another diagnosis 
arises during the evaluation that better explains that 
clinical presentation, then the diagnosis is “not MS.”
a: An attack (relapse; exacerbation) is defined as patient 
reported or objectively observed events typical of an 
acute inflammatory demyelinating event in the CNS, 
current or historical, with duration of at least 24 h, in the 
absence of fever or infection. It should be documented 
by contemporaneous neurological examination, but 
some historical events with symptoms and evolution 
characteristic for MS, but for which no objective 
neurological findings are documented, can provide 
reasonable evidence of a prior demyelinating event. 
Reports of paroxysmal symptoms (historical or current) 
should, however, consist of multiple episodes occurring 
over not less than 24 hs. Before a definite diagnosis of 
MS can be made, at least 1 attack must be corroborated 
by findings on neurological examination, visual evoked 
potential response in patients reporting prior visual 
disturbance, or MRI consistent with demyelination in 
the area of the CNS implicated in the historical report of 
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neurological symptoms.
b: Clinical diagnosis based on objective clinical findings 
for 2 attacks is most secure. Reasonable historical 
evidence for 1 past attack in the absence of documented 
objective neurological findings can include historical 
events with symptoms and evolution characteristics for a 
prior inflammatory demyelinating event; at least 1 attack, 
however, must be supported by objective findings.
c: No additional tests are required. However, it is 
desirable that any diagnosis of MS be made with access 
Management of MS in children
to imaging based on these criteria. If imaging or other 
tests (for instance, analysis of CSF) are undertaken and 
are negative, extreme caution needs to be taken before 
making a diagnosis of MS, and alternative diagnoses 
must be considered. There must be no better explanation 
for the clinical presentation, and objective evidence must 
be present to support a diagnosis of MS.
d: Gadolinium-enhancing lesions are not required; 
symptomatic lesions are excluded from consideration in 
subjects with brain stem or spinal cord syndromes.
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